Diversicare Healthcare Services (DVCR) 10-Q 2 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Diversicare Healthcare Services, Inc.
Entity Central Index Key	919,956
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,457,836

Interim Consolidated Balance Sh

Interim Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 3,295	$ 4,263
Receivables, less allowance for doubtful accounts of $13,011 and $10,326, respectively	63,867	62,152
Other receivables	1,115	1,193
Prepaid expenses and other current assets	3,164	3,623
Income tax refundable	525	431
Current assets of discontinued operations	45	28
Total current assets	72,011	71,690
PROPERTY AND EQUIPMENT, at cost	145,416	128,822
Less accumulated depreciation and amortization	(76,028)	(69,022)
Property and equipment, net	69,388	59,800
OTHER ASSETS:
Deferred income taxes, net	21,092	21,185
Deferred lease and other costs, net	149	193
Acquired leasehold interest, net	6,789	7,075
Other noncurrent assets	2,990	3,108
Total other assets	31,020	31,561
Total assets	172,419	163,051
CURRENT LIABILITIES:
Current portion of long-term debt and capitalized lease obligations	10,582	7,715
Trade accounts payable	13,051	12,972
Current liabilities of discontinued operations	461	427
Accrued expenses:
Payroll and employee benefits	20,178	20,108
Self-insurance reserves, current portion	10,099	9,401
Provider taxes	3,116	3,114
Other current liabilities	5,960	4,432
Total current liabilities	63,447	58,169
NONCURRENT LIABILITIES:
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net	76,708	72,145
Self-insurance reserves, less current portion	11,657	11,766
Other noncurrent liabilities	8,337	9,551
Total noncurrent liabilities	96,702	93,462
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Common stock, authorized 20,000,000 shares, $.01 par value, 6,690,000 and 6,592,000 shares issued, and 6,458,000 and 6,361,000 shares outstanding, respectively	67	66
Treasury stock at cost, 232,000 shares of common stock	(2,500)	(2,500)
Paid-in capital	22,496	21,935
Accumulated deficit	(8,243)	(8,276)
Accumulated other comprehensive income	450	195
Total shareholders’ equity	12,270	11,420
Total liabilities and shareholder's equity	$ 172,419	$ 163,051

Interim Consolidated Balance S3

Interim Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 13,011	$ 10,326
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	20,000,000	20,000,000
Common stock, shares issued (shares)	6,690,000	6,592,000
Common stock, shares outstanding (shares)	6,458,000	6,361,000
Treasury stock, shares (shares)	232,000	232,000

Interim Consolidated Statements

Interim Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
PATIENT REVENUES, net	$ 146,377,000	$ 97,313,000	$ 430,427,000	$ 291,063,000
EXPENSES:
Operating	118,104,000	79,441,000	341,937,000	236,444,000
Lease and rent expense	13,791,000	6,865,000	41,297,000	20,971,000
Professional liability	2,617,000	1,977,000	8,011,000	5,977,000
General and administrative	8,083,000	7,420,000	25,277,000	21,035,000
Depreciation and amortization	2,988,000	1,992,000	8,095,000	6,055,000
Lease termination costs (receipts)	(180,000)	0	(180,000)	2,008,000
Total expenses	145,403,000	97,695,000	424,437,000	292,490,000
OPERATING INCOME (LOSS)	974,000	(382,000)	5,990,000	(1,427,000)
OTHER INCOME (EXPENSE):
Equity in net income of unconsolidated affiliate	0	130,000	0	191,000
Gain on sale of investment in unconsolidated affiliate			733,000	0
Interest expense, net	(1,668,000)	(1,201,000)	(4,692,000)	(3,429,000)
Hurricane costs	(232,000)	0	(232,000)	0
Debt retirement costs			0	(351,000)
Total other expense	(1,900,000)	(1,071,000)	(4,191,000)	(3,589,000)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(926,000)	(1,453,000)	1,799,000	(5,016,000)
BENEFIT FOR INCOME TAXES	345,000	495,000	(651,000)	1,834,000
INCOME (LOSS) FROM CONTINUING OPERATIONS	(581,000)	(958,000)	1,148,000	(3,182,000)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
Operating income (loss), net of tax benefit (expense) of ($1) and $12, respectively	1,000	(17,000)	(42,000)	(54,000)
NET LOSS	$ (580,000)	$ (975,000)	$ 1,106,000	$ (3,236,000)
Per common share – basic
Per common share – basic, Continuing operations (dollars per share)	$ (0.09)	$ (0.16)	$ 0.18	$ (0.51)
Per common share – basic, Discontinued operations (dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – basic (dollars per share)	(0.09)	(0.16)	0.17	(0.52)
Per common share – diluted
Per common share – diluted, Continuing operations (dollars per share)	(0.09)	(0.16)	0.18	(0.51)
Per common share – diluted, Discontinued operations (dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – diluted (dollars per share)	(0.09)	(0.16)	0.17	(0.52)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share)	$ 0.055	$ 0.055	$ 0.17	$ 0.17
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (shares)	6,294	6,212	6,274	6,195
Diluted (shares)	6,294	6,212	6,465	6,195

Interim Consolidated Statement5

Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Tax effect on operating income	$ (1)	$ 12	$ 25	$ 33

Interim Consolidated Statement6

Interim Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ (580)	$ (975)	$ 1,106	$ (3,236)
OTHER COMPREHENSIVE INCOME:
Change in fair value of cash flow hedge, net of tax	203	364	603	398
Less: reclassification adjustment for amounts recognized in net income	(115)	(118)	(348)	(381)
Total other comprehensive income	88	246	255	17
COMPREHENSIVE INCOME (LOSS)	$ (492)	$ (729)	$ 1,361	$ (3,219)

Interim Consolidated Statement7

Interim Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
NET INCOME (LOSS)	$ 1,106,000	$ (3,236,000)
Discontinued operations	(42,000)	(54,000)
Income (loss) from continuing operations	1,148,000	(3,182,000)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	8,095,000	6,055,000
Provision for doubtful accounts	6,407,000	5,785,000
Deferred income tax provision (benefit)	52,000	(2,329,000)
Provision for self-insured professional liability, net of cash payments	(168,000)	1,853,000
Stock-based compensation	766,000	721,000
Equity in net income of unconsolidated affiliate	0	(191,000)
Gain on sale of unconsolidated affiliate	(733,000)	0
Debt retirement costs	0	351,000
Provision for leases in excess of cash payments	(517,000)	(1,640,000)
Lease termination costs, net of cash payments	0	1,958,000
Deferred bonus	700,000	0
Other	388,000	463,000
Changes in assets and liabilities affecting operating activities:
Receivables, net	(8,387,000)	(2,071,000)
Prepaid expenses and other assets	459,000	(1,620,000)
Trade accounts payable and accrued expenses	1,977,000	(226,000)
Net cash provided by continuing operations	10,187,000	5,927,000
Discontinued operations	(241,000)	(3,572,000)
Net cash provided by operating activities	9,946,000	2,355,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(8,638,000)	(4,046,000)
Property acquisitions	(8,750,000)	(7,550,000)
Proceeds from sale of unconsolidated affiliate	1,100,000	0
Change in restricted cash	0	1,658,000
Net cash used in continuing operations	(16,288,000)	(9,938,000)
Discontinued operations	0	0
Net cash used in investing activities	(16,288,000)	(9,938,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt obligations	(24,381,000)	(70,883,000)
Proceeds from issuance of debt	31,574,000	80,855,000
Financing costs	(195,000)	(1,884,000)
Issuance and redemption of employee equity awards	(94,000)	(105,000)
Payment of common stock dividends	(1,038,000)	(1,025,000)
Payment for preferred stock restructuring	(492,000)	(477,000)
Net cash provided by financing activities	5,374,000	6,481,000
Discontinued operations	0	0
Net cash provided by financing activities	5,374,000	6,481,000
NET DECREASE IN CASH AND CASH EQUIVALENTS	(968,000)	(1,102,000)
CASH AND CASH EQUIVALENTS, beginning of period	4,263,000	4,585,000
CASH AND CASH EQUIVALENTS, end of period	3,295,000	3,483,000
SUPPLEMENTAL INFORMATION:
Cash payments of interest	3,989,000	2,906,000
Cash payments of income taxes	667,000	521,000
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Acquisition of equipment through capital lease	$ 507,000	$ 0

Business

Business	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas. As of September 30, 2017 , the Company’s continuing operations consist of 76 nursing centers with 8,457 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted and residential living beds.

Consolidation and Basis of Pres

Consolidation and Basis of Presentation of Financial Statements	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations. The sale resulted in a $1,366,000 gain in the fourth quarter of 2016. Subsequently, the Company recognized an additional gain of $733,000 for the nine -month period ended September 30, 2017 , related to the liquidation of remaining assets affiliated with the partnership. The interim consolidated financial statements for the three and nine month periods ended September 30, 2017 and 2016 , included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2017 , and the results of operations for the three and nine month periods ended September 30, 2017 and 2016 , and cash flows for the nine month periods ended September 30, 2017 and 2016 . The Company’s balance sheet information at December 31, 2016 , was derived from its audited consolidated financial statements as of December 31, 2016 . The results of operations for the periods ended September 30, 2017 and 2016 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 .

Recent Accounting Guidance

Recent Accounting Guidance	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
RECENT ACCOUNTING GUIDANCE	RECENT ACCOUNTING GUIDANCE In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 will be effective for annual and interim reporting periods beginning after December 15, 2017. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company will elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from patient contracts, including revenue recognition policies to identify performance obligations, assets recognized from costs incurred to obtain and fulfill a contract, and significant judgments in measurement and recognition. The Company is determining the impact of adopting Topic 606 on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. We expect to complete our assessment on variable considerations in 2017. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a $7,644,000 reclassification between current deferred income taxes and non-current deferred income taxes as of December 31, 2016. In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances. The Company is still evaluating the effect, if any, the standard will have on the Company's consolidated financial condition and results of operations. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being asset acquisitions. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.

Long-Term Debt and Interest Rat

Long-Term Debt and Interest Rate Swap	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
LONG-TERM DEBT AND INTEREST RATE SWAP	LONG-TERM DEBT AND INTEREST RATE SWAP The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100,000,000 allocated between a $72,500,000 Mortgage Loan ("Amended Mortgage Loan") and a $27,500,000 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000,000 term loan facility and a $12,500,000 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162,000 and are being amortized over the five -year term of the agreements. Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500,000 with a five -year maturity through February 26, 2021, and a $27,500,000 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25 -year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75% , respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000,000 . The Amended Mortgage Loan balance was $67,525,000 as of September 30, 2017 , consisting of $65,025,000 on the term loan facility with an interest rate of 5.25% and $2,500,000 on the acquisition loan facility with an interest rate of 6.0% . The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500,000 in the Amended Revolver to $52,250,000 ; provided that the maximum revolving facility be reduced to $42,250,000 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250,000 . On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000,000 to $15,000,000 . Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500,000 . As of September 30, 2017 , the Company had $20,000,000 borrowings outstanding under the Amended Revolver compared to $15,000,000 outstanding as of December 31, 2016 . The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,408,000 outstanding as of September 30, 2017 . Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $38,255,000 , the balance available for borrowing under the Amended Revolver was $4,847,000 at September 30, 2017 . The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2017 . Interest Rate Swap Transaction As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,775,000 as of September 30, 2017 . The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2017 , the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net liability of $20,000 at September 30, 2017 . The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The liability related to the change in the interest rate swap included in accumulated other comprehensive income at September 30, 2017 is $12,000 , net of the income tax benefit of $8,000 . As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement .

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Health Care Organizations [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Professional Liability and Other Liability Insurance The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, and Texas. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000 . The remaining nursing centers are covered by one of seven claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying self-insured retention levels per claim and varying aggregate policy limits. Reserve for Estimated Self-Insured Professional Liability Claims Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $19,592,000 as of September 30, 2017 . This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. As of September 30, 2017 , the Company is engaged in 71 professional liability lawsuits. Seven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $6,077,000 and $2,779,000 for the nine months ended September 30, 2017 and 2016 , respectively. Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made. Civil Investigative Demand ("CID") In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA"). In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against two of its centers. In response to civil investigative demands (“CIDs”) and informal requests, the Company has provided to the DOJ documents and information relating to the Company’s practices and policies for rehabilitation and other services, relating to the preadmission evaluation forms ("PAEs") required by TennCare, and relating to the Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. The DOJ has also obtained testimony from current and former employees of the Company. The DOJ’s civil investigation has been focused on six of our centers, but the DOJ has indicated that all of the Company’s centers are the subject of the investigation related to rehabilitation therapy. In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs. The Company has responded to this subpoena and provided additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations. Other Insurance With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely self-insured for workers' compensation exposure. From July 1, 2008 through September 30, 2017 , the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000 . The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $871,000 at September 30, 2017 . The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,652,000 as of September 30, 2017 . The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. As of September 30, 2017 , the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,293,000 at September 30, 2017 . The differences between actual settlements and reserves are included in expense in the period finalized. Hurricanes Harvey and Irma During the nine months ended September 30, 2017 , Hurricanes Harvey and Irma impacted four of our centers in Texas and one center in Florida, respectively. We incurred $0.2 million of costs which were recorded as hurricane costs in the accompanying interim consolidated statements of operations for the three and nine months ended September 30, 2017 . The Company continues to evaluate the impact of the hurricanes on the business and intends to file a claim under its insurance program for damages.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Overview of Plans In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. This plan has expired and no new grants may be made under the 2005 Plan. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors. In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers . The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150,000 shares to 350,000 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028. In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380,000 shares to 680,000 shares. No grants can be made under the 2010 Plan after May 31, 2027. Equity Grants and Valuations During the nine months ended September 30, 2017 and 2016 , the Compensation Committee of the Board of Directors approved grants totaling approximately 88,000 and 83,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. Prior to 2016 , the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. Summarized activity of the equity compensation plans is presented below: Weighted Options/ Average SOSARs Exercise Price Outstanding, December 31, 2016 231,000 $ 6.97 Granted — — Exercised — — Expired or cancelled (17,000 ) 11.29 Outstanding, September 30, 2017 214,000 $ 6.64 Exercisable, September 30, 2017 209,000 $ 6.55 Weighted Average Restricted Grant Date Shares Fair Value Outstanding, December 31, 2016 153,000 $ 9.47 Granted 88,000 9.98 Dividend Equivalents 3,000 10.35 Vested (74,000 ) 9.03 Cancelled (1,000 ) 9.98 Outstanding, September 30, 2017 169,000 $ 9.94 Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows: Weighted Average Restricted Grant Date Share Units Fair Value Outstanding, December 31, 2016 54,000 $ 11.10 Granted 26,000 9.98 Dividend Equivalents 1,000 10.35 Vested (37,000 ) 12.11 Cancelled — — Outstanding, September 30, 2017 44,000 $ 9.59 The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model. In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. While no SOSARs or Options were granted during 2017 and 2016 , previously granted SOSARs and Options remain outstanding as of September 30, 2017 . The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2017 : Weighted Average Intrinsic Intrinsic Range of Exercise Grants Value-Grants Grants Value-Grants Exercise Prices Prices Outstanding Outstanding Exercisable Exercisable $10.21 to $10.88 $ 10.63 46,000 $ 40,000 41,000 $ 33,000 $2.37 to $6.21 $ 5.55 168,000 $ 1,000,000 168,000 $ 1,000,000 214,000 209,000 Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $766,000 and $721,000 in the nine month periods ended September 30, 2017 and 2016 , respectively.

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER COMMON SHARE	EARNINGS (LOSS) PER COMMON SHARE Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income (loss) Income (loss) from continuing operations $ (581 ) $ (958 ) 1,148 (3,182 ) Income (loss) from discontinued operations, net of income taxes 1 (17 ) (42 ) (54 ) Net income (loss) $ (580 ) $ (975 ) $ 1,106 $ (3,236 ) Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income (loss) per common share: Per common share – basic Income (loss) from continuing operations $ (0.09 ) $ (0.16 ) $ 0.18 $ (0.51 ) Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – basic $ (0.09 ) $ (0.16 ) $ 0.17 $ (0.52 ) Per common share – diluted Income (loss) from continuing operations $ (0.09 ) $ (0.16 ) $ 0.18 $ (0.51 ) Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – diluted $ (0.09 ) $ (0.16 ) $ 0.17 $ (0.52 ) Weighted Average Common Shares Outstanding: Basic 6,294 6,212 6,274 6,195 Diluted 6,294 6,212 6,465 6,195 The effects of 46,000 and 231,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2017 and 2016 , respectively, because these securities would have been anti-dilutive.

Equity Method Investment

Equity Method Investment	9 Months Ended
	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
EQUITY METHOD INVESTMENT	EQUITY METHOD INVESTMENT The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the net profits and losses of the unconsolidated affiliate are reported as equity in net earnings or losses of unconsolidated affiliate in our statement of operations. For the nine -month period ended September 30, 2017 , the equity in the net income of an unconsolidated affiliate was zero compared to $191,000 for the nine -month period ended September 30, 2016 . The proceeds received from the sale are considered in the calculation of the gain on sale of investment in unconsolidated affiliate in our statement of operations. For the nine -month period ended September 30, 2017 , the gain on the sale of investment in unconsolidated affiliate was $733,000 , related to the liquidation of remaining assets affiliated with the partnership.

Business Developments and Other

Business Developments and Other Significant Transactions	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS 2017 Acquisition On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103 -bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750,000 . In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500,000 , which is described in Note 4 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. As a result of this business combination transaction, the Company preliminarily allocated the purchase price of $8,750,000 based on the fair value of the acquired net assets. The preliminary allocation for the building, land and furniture, fixtures and equipment were $7,332,000 , $715,000 , and $703,000 , respectively. 2017 Lease Termination On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250,000 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the three and nine months ended September 30, 2017 . For accounting purposes, this transaction was not reported as a discontinued operation, which is in accordance with the modified authoritative guidance for reporting discontinued operations, effective January 1, 2015. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. Golden Living Transaction On August 15, 2016, the Company entered into an Operation Transfer Agreement with Golden Living (the "Lessor") to assume the operations of 22 centers in Alabama and Mississippi. On October 1, 2016, the Company entered into a Master Lease Agreement (the "Lease") with Golden Living to directly lease eight centers located in Mississippi from the Lessor, which include: (i) a 152 -bed skilled nursing center known as Golden Living Center - Amory; (ii) a 130 -bed skilled nursing center known as Golden Living Center - Batesville; (iii) a 58 -bed skilled nursing center known as Golden Living Center - Brook Manor; (iv) a 119 -bed skilled nursing center known as Golden Living Center - Eupora; (v) a 140 -bed skilled nursing center known as Golden Living Center - Ripley; (vi) a 140 -bed skilled nursing center known as Golden Living Center - Southaven; (vii) a 120 -bed skilled nursing center known as Golden Living Center - Eason Blvd; (viii) a 60 -bed skilled nursing center known as Golden Living Center - Tylertown. The Lease is triple net and has an initial term of ten years with two separate five year options to extend the term. The Company also assumed the individual leases of a 120 -bed center known as Broadmoor Nursing Home, with an initial lease term of ten years with first year rent of $540,000 , escalating to $780,000 in the second year, and 2% annually thereafter, and a 99 -bed skilled nursing center known as Leake County Nursing Home, with a lease term of two years with annual rent of $300,000 . On November, 1 2016, the Company amended and restated the Lease ("Amended Lease") with the Lessor to directly lease an additional twelve centers located in Alabama from the Lessor, which include: (i) a 87 -bed skilled nursing center known as Golden Living Center - Arab; (ii) a 180 -bed skilled nursing center known as Golden Living Center - Meadowood; (iii) a 132 -bed skilled nursing center known as Golden Living Center - Riverchase; (iv) a 100 -bed skilled nursing center known as Golden Living Center - Boaz; (v) a 154 -bed skilled nursing center known as Golden Living Center - Foley; (vi) a 50 -bed skilled nursing center known as Golden Living Center - Hueytown; (vii) a 85 -bed skilled nursing center known as Golden Living Center - Lanett; (viii) a 138 -bed skilled nursing center known as Golden Living Center - Montgomery; (ix) a 120 -bed skilled nursing center known as Golden Living Center - Oneonta; (x) a 173 -bed skilled nursing center known as Golden Living Center - Oxford; (xi) a 94 -bed skilled nursing center known as Golden Living Center - Pell City; (xii) a 123 -bed skilled nursing center known as Golden Living Center - Winfield. The Amended Lease is triple net and has an initial term of ten years with two separate five years options to extend the term. Base rent for the amended lease is $24,675,000 for the first year and escalates 2% annually thereafter. 2016 Acquisitions On February 26, 2016, the Company exercised its purchase options to acquire the real estate assets for Diversicare of Hutchinson in Hutchinson, Kansas and Clinton Place in Clinton, Kentucky for $4,250,000 and $3,300,000 , respectively. The Company has operated these facilities since February 2015 and April 2012, respectively. Hutchinson is an 85 -bed skilled nursing facility, and Clinton is an 88 -bed skilled nursing facility. As a result of the consummation of the Agreements, the Company allocated the purchase price and acquisition costs among the assets acquired based on their relative fair value at the acquisition date. The allocation of the purchase price was determined with the assistance of a third-party real estate valuation firm. The allocation for the assets acquired is as follows: Hutchinson Clinton Place Purchase Price $ 4,250,000 $ 3,300,000 Acquisition Costs 43,000 34,000 $ 4,293,000 $ 3,334,000 Allocation: Buildings 3,443,000 2,898,000 Land 365,000 267,000 Furniture, Fixtures and Equipment 485,000 169,000 $ 4,293,000 $ 3,334,000 2016 Lease Termination On May 31, 2016, the Company entered into an Agreement with Avon Ohio, LLC to amend the original lease agreement, thus terminating the Company's right of possession of the facility in Avon, Ohio. As a result, the Company incurred lease termination costs of $2,008,000 in the second quarter of 2016. Under the amended agreement, the Company is required to pay $300,000 per year through the term of the original lease agreement, July 31, 2024. For accounting purposes, this transaction was not reported as a discontinued operation, which is in accordance with the modified authoritative guidance for reporting discontinued operations, effective January 1, 2015. A disposal is now required to be reported in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. 2016 Sale of Investment in Unconsolidated Affiliate On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366,000 gain in the fourth quarter of 2016. Subsequently, we recognized an additional gain of $733,000 for the nine -month period ended September 30, 2017 , related to the final liquidation of remaining net assets affiliated with the partnership.

Consolidation and Basis of Pr17

Consolidation and Basis of Presentation of Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation	The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The Company's share of the profits and losses from this investment are reported as equity in earnings of investment in an unconsolidated affiliate and the proceeds received from the sale are reported under the heading "Gain on sale of investment in unconsolidated affiliate" in the accompanying interim consolidated statements of operations.
Basis of Accounting	The interim consolidated financial statements for the three and nine month periods ended September 30, 2017 and 2016 , included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2017 , and the results of operations for the three and nine month periods ended September 30, 2017 and 2016 , and cash flows for the nine month periods ended September 30, 2017 and 2016 . The Company’s balance sheet information at December 31, 2016 , was derived from its audited consolidated financial statements as of December 31, 2016 . The results of operations for the periods ended September 30, 2017 and 2016 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 .
Recent Accounting Guidance	In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 will be effective for annual and interim reporting periods beginning after December 15, 2017. The Company will adopt the requirements of this standard effective January 1, 2018. The new standard may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). The Company will elect to apply the modified retrospective approach upon adoption. Additionally, the new guidance requires enhanced disclosures about the nature, amount, timing, and uncertainty of revenue and cash flows arising from patient contracts, including revenue recognition policies to identify performance obligations, assets recognized from costs incurred to obtain and fulfill a contract, and significant judgments in measurement and recognition. The Company is determining the impact of adopting Topic 606 on its revenue recognition policies, procedures and control framework and the resulting impact on its consolidated financial position, results of operation and cash flows. The Company is in the process of reviewing revenue sources and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. We expect to complete this process in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with government payors, state Medicaid programs and bundled payment of care programs. Due to the many forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new standard could have an impact on the revenue recognized for variable consideration. We expect to complete our assessment on variable considerations in 2017. Industry guidance is continuing to develop, and any conclusions in the final industry guidance that is inconsistent with the Company's application could result in changes to the Company's expectations regarding the impact of the new standard on the Company's financial statements. Additionally, the adoption of the new standard will impact the presentation on the Company's statement of operations. After the adoption, the majority of what is currently classified as bad debt expense will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenues. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which changes how deferred taxes are classified on the Company's balance sheets. The Company adopted ASU No. 2015-17 as of January 1, 2017, and the new standard was applied on a retrospective basis. The adoption of this guidance resulted in a $7,644,000 reclassification between current deferred income taxes and non-current deferred income taxes as of December 31, 2016. In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for building and equipment operating leases and will result in a significant increase in the assets and liabilities on the consolidated balance sheet. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which will require the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on our consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017. The Company plans to adopt this standard on January 1, 2018. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017, with early adoption permitted in certain circumstances. The Company is still evaluating the effect, if any, the standard will have on the Company's consolidated financial condition and results of operations. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being asset acquisitions. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. Early adoption is permitted. The Company does not presently believe adoption of this new standard will be material to its consolidated financial statements. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging - Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summarized activity of equity compensation plans	Summarized activity of the equity compensation plans is presented below: Weighted Options/ Average SOSARs Exercise Price Outstanding, December 31, 2016 231,000 $ 6.97 Granted — — Exercised — — Expired or cancelled (17,000 ) 11.29 Outstanding, September 30, 2017 214,000 $ 6.64 Exercisable, September 30, 2017 209,000 $ 6.55
Schedule of summarized activity of Restricted Share Units	Weighted Average Restricted Grant Date Shares Fair Value Outstanding, December 31, 2016 153,000 $ 9.47 Granted 88,000 9.98 Dividend Equivalents 3,000 10.35 Vested (74,000 ) 9.03 Cancelled (1,000 ) 9.98 Outstanding, September 30, 2017 169,000 $ 9.94 Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows: Weighted Average Restricted Grant Date Share Units Fair Value Outstanding, December 31, 2016 54,000 $ 11.10 Granted 26,000 9.98 Dividend Equivalents 1,000 10.35 Vested (37,000 ) 12.11 Cancelled — — Outstanding, September 30, 2017 44,000 $ 9.59
Schedule of summarized information regarding stock options and SOSAR grants outstanding	The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2017 : Weighted Average Intrinsic Intrinsic Range of Exercise Grants Value-Grants Grants Value-Grants Exercise Prices Prices Outstanding Outstanding Exercisable Exercisable $10.21 to $10.88 $ 10.63 46,000 $ 40,000 41,000 $ 33,000 $2.37 to $6.21 $ 5.55 168,000 $ 1,000,000 168,000 $ 1,000,000 214,000 209,000

Earnings (Loss) Per Common Sh19

Earnings (Loss) Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Basic and diluted net income (loss) per common share	Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income (loss) Income (loss) from continuing operations $ (581 ) $ (958 ) 1,148 (3,182 ) Income (loss) from discontinued operations, net of income taxes 1 (17 ) (42 ) (54 ) Net income (loss) $ (580 ) $ (975 ) $ 1,106 $ (3,236 ) Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income (loss) per common share: Per common share – basic Income (loss) from continuing operations $ (0.09 ) $ (0.16 ) $ 0.18 $ (0.51 ) Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – basic $ (0.09 ) $ (0.16 ) $ 0.17 $ (0.52 ) Per common share – diluted Income (loss) from continuing operations $ (0.09 ) $ (0.16 ) $ 0.18 $ (0.51 ) Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – diluted $ (0.09 ) $ (0.16 ) $ 0.17 $ (0.52 ) Weighted Average Common Shares Outstanding: Basic 6,294 6,212 6,274 6,195 Diluted 6,294 6,212 6,465 6,195

Business Developments and Oth20

Business Developments and Other Significant Transactions (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of allocation for net assets acquired	The allocation for the assets acquired is as follows: Hutchinson Clinton Place Purchase Price $ 4,250,000 $ 3,300,000 Acquisition Costs 43,000 34,000 $ 4,293,000 $ 3,334,000 Allocation: Buildings 3,443,000 2,898,000 Land 365,000 267,000 Furniture, Fixtures and Equipment 485,000 169,000 $ 4,293,000 $ 3,334,000

Business (Narrative) (Details)

Business (Narrative) (Details)	Sep. 30, 2017statecenterbed
Accounting Policies [Line Items]
Number of states in which entity operates | state	10
Number of nursing centers | center	76
Number of licensed nursing beds	8,457
Number of nursing center facilities owned | center	18
Number of nursing center facilities leased | center	58
Number of licensed assisted and residential living beds	496
Minimum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	48
Maximum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	320

Consolidated and Basis of Prese

Consolidated and Basis of Presentation of Financial Statements (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2016USD ($)investment	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Schedule of Equity Method Investments [Line Items]
Number of equity method investments sold | investment	1
Gain on sale of investment in unconsolidated affiliate		$ 733	$ 0
Unnamed pharmacy joint venture
Schedule of Equity Method Investments [Line Items]
Gain on sale of investment in unconsolidated affiliate	$ 1,366	$ 733

Recent Accounting Guidance (Nar

Recent Accounting Guidance (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred income taxes, net	$ 21,092	$ 21,185
Accounting Standards Update 2015-17
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of current deferred income tax assets		7,644
Deferred income taxes, net		$ 7,644

Long-Term Debt and Interest R24

Long-Term Debt and Interest Rate Swap (Narrative) (Details)	Dec. 29, 2016USD ($)	Feb. 26, 2016USD ($)center	Sep. 30, 2017USD ($)letter_of_credit	Aug. 01, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 28, 2016USD ($)	Oct. 03, 2016USD ($)
Line of Credit Facility [Line Items]
Accumulated other comprehensive income (loss)			$ 450,000			$ 195,000
Interest rate swap
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives			$ 28,775,000
Annual fixed rate percentage			5.79%
Net liability based on interest rate swap valuation model			$ 20,000
Accumulated other comprehensive income (loss)			(12,000)
Income tax benefit, interest rate swap			$ 8,000
Amended and restated credit agreement
Line of Credit Facility [Line Items]
Loan acquisition costs		$ 2,162,000
Number of letters of credit | letter_of_credit			11
Credit agreement | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 100,000,000
Term of agreements		5 years
Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 72,500,000
Term of agreements		5 years
Period of amortization		25 years
Amended mortgage loan balance			$ 67,525,000
Number of owned nursing centers to secure Amended Mortgage Loan | center		18
Mortgage loan | Amended and restated credit agreement | Interest rate swap
Line of Credit Facility [Line Items]
Debt interest rate at period end		5.79%
Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 27,500,000	38,255,000	$ 42,250,000	$ 52,250,000			$ 52,250,000
Borrowings outstanding			20,000,000			$ 15,000,000
Balance available for borrowing under revolving credit center			$ 4,847,000
Amended revolver | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage		4.00%
Letter of credit | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 15,000,000						$ 10,000,000
Annual fees for letters of credit issued under Revolver (as a percentage)	3.00%
Mortgage term loan | Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 60,000,000
Debt interest rate at period end			5.25%
Amended mortgage loan balance			$ 65,025,000
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives		$ 30,000,000
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage		4.00%
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity		$ 12,500,000
Debt interest rate at period end			6.00%
Amended mortgage loan balance			$ 2,500,000
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage		4.75%
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Letters of credit security deposit for a lease			$ 13,408,000

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)lawsuitfacilitypolicy	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)lawsuitfacilitycenterpolicy	Sep. 30, 2016USD ($)	Oct. 31, 2014facility
Malpractice Insurance [Line Items]
Number of professional liability lawsuits | lawsuit	71		71
Cash expenditures for self-insured professional liability costs			$ 6,077,000	$ 2,779,000
Other Insurance
Liability for workers compensation claims	$ 871,000		871,000
Workers compensation insurance, non current receivable for excess premiums paid	1,652,000		1,652,000
Hurricane Harvey and Irma
Hurricane costs	$ 232,000	$ 0	$ 232,000	$ 0
Unfavorable regulatory action | Potential violations of false claims act
Malpractice Insurance [Line Items]
Number of facilities | facility	6		6		2
Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Liability for reported and estimated future claims	$ 19,592,000		$ 19,592,000
Prefunded deductible policy
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim			500,000
Other Insurance
Insurance policy coverage limits per claim			500,000
Professional liability insurance, annual coverage limit per facility			3,000,000
Health insurance, maximum self-insured annual amount per individual	175,000		175,000
Liability for reported claims and estimates for incurred but unreported claims	$ 1,293,000		1,293,000
SHC Risk Carriers, Inc | Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim			500,000
Malpractice insurance annual sublimit per center			1,000,000
Aggregate policy limit			5,000,000
Other Insurance
Insurance policy coverage limits per claim			500,000
Unaffiliated entities | Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim			1,000,000
Malpractice insurance annual sublimit per center			$ 3,000,000
Number of types of professional liability insurance policies | policy	7		7
Other Insurance
Insurance policy coverage limits per claim			$ 1,000,000
Scheduled for trial or arbitration over next 12 months
Malpractice Insurance [Line Items]
Number of professional liability lawsuits | lawsuit	7		7
TEXAS
Hurricane Harvey and Irma
Number of locations impacted by catastrophe | center			4
FLORIDA
Hurricane Harvey and Irma
Number of locations impacted by catastrophe | center			1

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	May 31, 2017	Jun. 30, 2016	Jun. 29, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 766	$ 721
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant of restricted common stock (shares)	88,000	83,000
Restricted Stock | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Restricted Stock | Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Restricted Stock | Third anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Stock Options and Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payment award, expiration period	10 years
SOSARs granted in period (shares)	0		0
Stock Options and Stock Appreciation Rights (SARs) | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Stock Options and Stock Appreciation Rights (SARs) | Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Stock Options and Stock Appreciation Rights (SARs) | Third anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
2005 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (shares)	700,000
Expiration period	10 years
2008 Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of quoted market price offering rate	85.00%
Restriction period	2 years
Shares authorized under the plan (shares)					350,000	150,000
2010 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (shares)	680,000			380,000

Share-Based Compensation (Share

Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Awards, Vested and Expected to Vest, Outstanding and Exercisable) (Details) - Stock Options and Stock Appreciation Rights (SARs) shares in Thousands	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning (shares) | shares	231
Granted (shares) | shares	0
Exercised (shares) | shares	0
Expired or cancelled (shares) | shares	(17)
Outstanding, ending (shares) | shares	214
Exercisable (shares) | shares	209
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, beginning (dollars per share) | $ / shares	$ 6.97
Granted (dollars per share) | $ / shares	0
Exercised (dollars per share) | $ / shares	0
Expired or cancelled (dollars per share) | $ / shares	11.29
Outstanding, ending (dollars per share) | $ / shares	6.64
Exercisable, weighted average exercise price (dollars per share) | $ / shares	$ 6.55

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding, beginning (share) | shares	153
Granted (shares) | shares	88
Dividend equivalents (shares) | shares	3
Vested (shares) | shares	(74)
Cancelled (shares) | shares	(1)
Outstanding, ending (shares) | shares	169
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding, beginning (dollars per share) | $ / shares	$ 9.47
Granted (dollars per share) | $ / shares	9.98
Dividend equivalents (dollars per share) | $ / shares	10.35
Vested (dollars per share) | $ / shares	9.03
Cancelled (dollars per share) | $ / shares	9.98
Outstanding, ending (dollars per share) | $ / shares	$ 9.94
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding, beginning (share) | shares	54
Granted (shares) | shares	26
Dividend equivalents (shares) | shares	1
Vested (shares) | shares	(37)
Cancelled (shares) | shares	0
Outstanding, ending (shares) | shares	44
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding, beginning (dollars per share) | $ / shares	$ 11.10
Granted (dollars per share) | $ / shares	9.98
Dividend equivalents (dollars per share) | $ / shares	10.35
Vested (dollars per share) | $ / shares	12.11
Cancelled (dollars per share) | $ / shares	0
Outstanding, ending (dollars per share) | $ / shares	$ 9.59

Stock-Based Compensation (Sched

Stock-Based Compensation (Schedule of Awards Outstanding and Exercisable) (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise prices (dollars per share)	$ 6.64	$ 6.97
Grants outstanding (shares)	214
Grants exercisable (shares)	209
$10.21 to $10.88
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum (dollars per share)	$ 10.21
Range of exercise prices, maximum (dollars per share)	10.88
Weighted average exercise prices (dollars per share)	$ 10.63
Grants outstanding (shares)	46
Intrinsic value - grants outstanding	$ 40
Grants exercisable (shares)	41
Intrinsic value - grants exercisable	$ 33
$2.37 to $6.21
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum (dollars per share)	$ 2.37
Range of exercise prices, maximum (dollars per share)	6.21
Weighted average exercise prices (dollars per share)	$ 5.55
Grants outstanding (shares)	168
Intrinsic value - grants outstanding	$ 1,000
Grants exercisable (shares)	168
Intrinsic value - grants exercisable	$ 1,000

Earnings (Loss) Per Common Sh30

Earnings (Loss) Per Common Share (Basic and Diluted Net Income (Loss) Per Common Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net income (loss)
Income (loss) from continuing operations	$ (581)	$ (958)	$ 1,148	$ (3,182)
Income (loss) from discontinued operations, net of income taxes	1	(17)	(42)	(54)
Net income (loss)	$ (580)	$ (975)	$ 1,106	$ (3,236)
Per common share – basic
Income (loss) from continuing operations (dollars per share)	$ (0.09)	$ (0.16)	$ 0.18	$ (0.51)
Loss from discontinued operations (dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – basic (dollars per share)	(0.09)	(0.16)	0.17	(0.52)
Per common share – diluted
Income (loss) from continuing operations (dollars per share)	(0.09)	(0.16)	0.18	(0.51)
Loss from discontinued operations (dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – diluted (dollars per share)	$ (0.09)	$ (0.16)	$ 0.17	$ (0.52)
Weighted Average Common Shares Outstanding:
Basic (shares)	6,294	6,212	6,274	6,195
Diluted (shares)	6,294	6,212	6,465	6,195

Earnings (Loss) Per Common Sh31

Earnings (Loss) Per Common Share (Narrative) (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Antidilutive shares excluded from computation of diluted earnings per share (shares)	46	231

Equity Method Investment (Narra

Equity Method Investment (Narrative) (Details)	3 Months Ended			9 Months Ended
	Sep. 30, 2017USD ($)	Dec. 31, 2016investment	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Equity Method Investments and Joint Ventures [Abstract]
Number of equity method investments sold | investment		1
Equity in net income of unconsolidated affiliate	$ 0		$ 130,000	$ 0	$ 191,000
Gain on sale of investment in unconsolidated affiliate				$ 733,000	$ 0

Business Developments and Oth33

Business Developments and Other Significant Transactions (Narrative) (Details)

Jun. 08, 2017USD ($)

Nov. 01, 2016USD ($)facilityoptionbed

Oct. 01, 2016USD ($)facilitybed

May 31, 2016USD ($)

Feb. 26, 2016USD ($)bed

Sep. 30, 2017USD ($)centerbed

Dec. 31, 2016USD ($)

Sep. 30, 2016USD ($)

Jun. 30, 2016USD ($)

Sep. 30, 2017USD ($)centerbed

Sep. 30, 2016USD ($)

Jul. 01, 2017bed

Jun. 30, 2017USD ($)

Aug. 15, 2016facility

Business Acquisition [Line Items]

Number of licensed nursing beds

8,457

8,457

Cash termination payment | $

$ 13,791,000

$ 6,865,000

$ 41,297,000

$ 20,971,000

Number of nursing centers | center

76

76

Property acquisitions | $

$ 8,750,000

7,550,000

Gain on sale of investment in unconsolidated affiliate | $

733,000

$ 0

Avon Ohio, LLC

Business Acquisition [Line Items]

Lease termination costs | $

$ 2,008,000

Lease termination fees, future annual payment amounts | $

$ 300,000

Selma Nursing Centers

Business Acquisition [Line Items]

Number of licensed nursing beds

103

Purchase price | $

$ 8,750,000

Buildings acquired | $

7,332,000

Land acquired | $

715,000

Furniture, fixtures and equipment acquired | $

$ 703,000

Golden Living

Business Acquisition [Line Items]

Number of nursing centers | facility

22

Broadmoor Manor

Business Acquisition [Line Items]

Number of licensed nursing beds

120

Term of contract

10 years

Rent expense, base year rent | $

$ 540,000

Rent expense, increase during year two | $

$ 780,000

Annual rent increase, percentage

2.00%

Leake County Nursing Home

Business Acquisition [Line Items]

Number of licensed nursing beds

99

Term of contract

2 years

Rent expense, base year rent | $

$ 300,000

Armory, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

152

Batesville, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

130

Brook Manor, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

58

Eupora, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

119

Ripley, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

140

Southaven, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

140

Eason Blvd | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

120

Tylertown, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

60

Term of contract

10 years

Arab, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

87

Meadowood, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

180

Riverchase, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

132

Boaz, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

100

Foley, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

154

Hueytown, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

50

Lanett, MS | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

85

Montgomery, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

138

Oneonta, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

120

Oxford, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

173

Pell City, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

94

Winfield, AL | Golden Living

Business Acquisition [Line Items]

Number of licensed nursing beds

123

Unnamed pharmacy joint venture

Business Acquisition [Line Items]

Gain on sale of investment in unconsolidated affiliate | $

$ 1,366,000

733,000

Property subject to operating lease | Golden Living

Business Acquisition [Line Items]

Number of center locations | facility

12

8

Amended lease | Golden Living

Business Acquisition [Line Items]

Term of contract

10 years

Rent expense, base year rent | $

$ 24,675,000

Annual rent increase, percentage

2.00%

Maximum number of lease renewal periods | option

2

Operating leases, renewal term

5 years

Trend Health and Rehab of Carthage, LLC (Trend Health)

Business Acquisition [Line Items]

Cash termination payment | $

$ 250,000

$ 250,000

Diversicare of Hutchinson | Hutchinson, Kansas

Business Acquisition [Line Items]

Number of licensed nursing beds

85

Property acquisitions | $

$ 4,250,000

Clinton Place | Clinton, Kentucky

Business Acquisition [Line Items]

Number of licensed nursing beds

88

Property acquisitions | $

$ 3,300,000

Mortgage term loan | Amended and restated credit agreement | Mortgage loan | Selma Nursing Centers

Business Acquisition [Line Items]

Increase to credit facility limit | $

$ 7,500,000

Business Developments and Oth34

Business Developments and Other Significant Transactions (Schedule of Assets Acquired) (Details) - USD ($) $ in Thousands	Feb. 26, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Property acquisitions		$ 8,750	$ 7,550
Assets acquired		$ 145,416		$ 128,822
Diversicare of Hutchinson | Hutchinson, Kansas
Business Acquisition [Line Items]
Property acquisitions	$ 4,250
Acquisition Costs	43
Total payment for acquisition	4,293
Assets acquired	4,293
Diversicare of Hutchinson | Buildings | Hutchinson, Kansas
Business Acquisition [Line Items]
Assets acquired	3,443
Diversicare of Hutchinson | Land | Hutchinson, Kansas
Business Acquisition [Line Items]
Assets acquired	365
Diversicare of Hutchinson | Furniture, Fixtures and Equipment | Hutchinson, Kansas
Business Acquisition [Line Items]
Assets acquired	485
Clinton Place | Clinton, Kentucky
Business Acquisition [Line Items]
Property acquisitions	3,300
Acquisition Costs	34
Total payment for acquisition	3,334
Assets acquired	3,334
Clinton Place | Buildings | Clinton, Kentucky
Business Acquisition [Line Items]
Assets acquired	2,898
Clinton Place | Land | Clinton, Kentucky
Business Acquisition [Line Items]
Assets acquired	267
Clinton Place | Furniture, Fixtures and Equipment | Clinton, Kentucky
Business Acquisition [Line Items]
Assets acquired	$ 169